BLCOBausch + Lomb Corporation
Price
+14%1YEnd-of-day closes, not the intraday tick.
Great business, demanding price
Quality strong, nothing alarming, demanding price, growth steady, the market undecided.
Bausch + Lomb is a subsidiary of Bausch Health Companies Inc. (“BHC”), with BHC directly or indirectly holding 310,449,643 Bausch + Lomb common shares, which represents approximately 88% of the issued and outstanding common shares of Bausch + Lomb, as of February 11, 2026. On August 6, 2020, BHC announced its plan to separate our eye health business into an independent publicly traded entity, separate from the remainder of BHC (the “Separation”).
In the company’s own words · 10-K filed Feb 18, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
Bausch + Lomb Corporation (BLCO) reported revenue of $1.39B in Q2 2026 (quarter ended Jun 30, 2026), up 9.1% from the same quarter a year earlier. That came with net loss of $14M. For the full year FY2025, revenue was $5.10B (+6.5% year on year) and net income −$360M. Its largest region in Q4 2024 (quarter ended Dec 31, 2024) was United Statesand Puerto Rico at $657M, 51% of the disclosed total, well ahead of Other Countries at 15%. The next results filing is expected around Oct 28, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Aug 12, 2026On August 6, 2026, Bausch + Lomb Corporation (the “Company”) filed a Current Report on Form 8-K (the “Initial 8-K”) regarding the resignation of certain members of its board of directors (the “Board”) and the appointment of Thomas J. Appio, Robert Chersi, Laurence Paul, M.D. and Barbara Trebbi to the Board, effective …Director or officer change · Form 8-K/A
- Aug 6, 2026The information set forth below under.Material agreement entered · Form 8-K
- Jul 29, 2026Bausch + Lomb Delivers Broad-Based Second-Quarter Growth, Raises Full-Year 2026 Guidance.Earnings release · press release
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Business segments
Q4 2024 · $1.28BThe company’s own SEC segment disclosure.
- United States and Puerto Rico$657.0M51%
- Other Countries$197.0M15%
- China$96.0M8%
- France$51.0M4%
- Japan$50.0M4%
- United Kingdom$35.0M3%
- Other (8)$194.0M15%
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.
Medical Instruments & Supplies
Ranks #8 of 21 by RyuScore